To include your compound in the COVID-19 Resource Center, submit it here.

Dinaciclib: Phase IIb/III started

Ligand began a Phase IIb/III trial to evaluate dinaciclib in patients with refractory CLL. The

Read the full 150 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE